malignancy
Conditions
Interventions
Test group:Arepidtan injection+Ondansetron tablets
Control group:Ondansetron tablets
Sponsors
Dandong First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The patient/family member signed an informed consent form and voluntarily joined this study; 2. Age = 18 years old, regardless of gender; 3. Patients with malignant tumors (including solid tumors and malignant hematological tumors) confirmed by pathology or histopathology; 4. Plan to use highly or moderately emetic chemotherapy drugs that comply with the NCCN guidelines and anti-tumor treatment related vomiting prevention and treatment guidelines; 5. Did not receive radiotherapy or chemotherapy within 2 weeks prior to participating in the experiment.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with severe liver, kidney, and heart dysfunction; 3. Patients who have experienced vomiting 24 hours before chemotherapy; 4. Patients with allergies to NK-1 RA and/or its excipients; 5. Patients with nausea and vomiting caused by other non tumor factors, who are taking other emetic drugs or Alcohol intoxication;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Emetic relief rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response rate in acute phase (0-24 hours) and delayed phase (25-120 hours);Proportion of subjects receiving remedial treatment;Time until treatment failure (based on the time of first vomiting episode or remedial treatment, whichever occurs first);FLIE rating;Hospital Anxiety and Depression Scale (HAD) score; | — |
Countries
China
Contacts
Public ContactJingzhe Jin
Dandong First Hospital
Outcome results
None listed